Last Updated : May 5, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort ascending | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Iressa | Gefitinib | Cancer, Lung , non-small cell | Do not list | Complete | ||
| Evra | Norgelestromin/ethinyl estradiol | Contraceptive, patch | Do not list | Complete | ||
| Replagal | Agalsidase alfa | Fabry Disease | Do not list | Complete | ||
| Fabrazyme | Agalsidase beta | Fabry Disease | Do not list | Complete | ||
| Viread | Tenofovir disoproxil fumarate | HIV infection | Do not list | Complete | ||
| Adderall XR | Mixed amphetamine salts | Attention deficit hyperactivity disorder | Do not list | Complete | ||
| Zavesca | Miglustat | Gaucher disease | Do not list | Complete | ||
| Ciprodex | Ciprofloxacin hydrochloride and dexamethasone otic suspension | Otitis media with otorrhea & otitis externa, acute | Do not list | Complete | ||
| Forteo | Teriparatide (rDNA origin) injection | Osteoporosis | Do not list | Complete | ||
| Gynazole.1 | Butoconazole nitrate | Vaginal infection | Do not list | Complete |
Last Updated : May 5, 2024